Cart
sales@molnova.com
Epimedin B
CAS No. 110623-73-9
Epimedin B( —— )
Catalog No. M17818 CAS No. 110623-73-9
Epimedin B has potential activity against osteoporosis by stimulating osteoblasts.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 142 | In Stock |
|
| 10MG | 216 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEpimedin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionEpimedin B has potential activity against osteoporosis by stimulating osteoblasts.
-
DescriptionEpimedin B has potential activity against osteoporosis by stimulating osteoblasts.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number110623-73-9
-
Formula Weight808.78
-
Molecular FormulaC38H48O19
-
Purity>98% (HPLC)
-
SolubilityDMSO : 33.33 mg/mL. 41.21 mM;
-
SMILESCC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OC4C(C(C(C(O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)OC6C(C(C(CO6)O)O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
CK-101
CK-101 (RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC.
-
Lapatinib
A reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
AZ7550 hydrochloride
AZ7550 hydrochloride, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
